Table 6.
Relationship between fractional incorporation of plasma palmitate into intramyocellular 16:0 ceramide and clinical parameters
| IMF 13C16 16:0 Cer |
SS 13C16 S16:0 Cer |
|||
|---|---|---|---|---|
| γ | P value | γ | P value | |
| Age | –0.307 | 0.073 | 0.329 | 0.050 |
| BMI | –0.432 | 0.010 | –0.417 | 0.014 |
| Fasting glucose | –0.140 | 0.438 | –0.017 | 0.925 |
| Postprandial glucose | –0.053 | 0.764 | –0.061 | 0.732 |
| HOMA-IR | –0.066 | 0.715 | –0.048 | 0.795 |
| Fasting insulin | –0.041 | 0.815 | –0.068 | 0.701 |
| Postprandial insulin | –0.141 | 0.419 | –0.133 | 0.452 |
| Plasma triglycerides | –0.037 | 0.836 | –0.059 | 0.744 |
| Fat mass | –0.335 | 0.049 | –0.328 | 0.059 |
| UBSQ fat mass | –0.311 | 0.069 | –0.344 | 0.046 |
| LBSQ fat mass | –0.290 | 0.092 | –0.252 | 0.151 |
| Visceral fat mass | –0.273 | 0.113 | –0.194 | 0.272 |
| Plasma palmitate (0–90 min) | 0.050 | 0.777 | –0.092 | 0.603 |
| Plasma palmitate (150–330 min) | –0.001 | 0.998 | –0.079 | 0.657 |
Fractional contribution of plasma palmitate to intramyocellular ceramide was at the time of the second biopsy.